BIRC5 and neoplasm: However, due to its high priority as a tumor antigen, we sought to extend the recombinant virus vaccine platform we have described previously, which uses a replication deficient adenovirus as a primary vaccine followed by a rhabdovirus-vectored boost, to target murine survivin in pre-clinical mouse models [8].